Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China
Xianan Guo·Yiding Chen·Shiyao Hu·Yuqin Ding·Bojian Xie·Yangjun Cai·Huihui Chen·Xiawei Li·Shiwei Guo·Yanyan Wang·Yunxiang Zhou·P Li
Abstract Background CDK4/6 inhibitors combined with endocrine therapy constitute the global first-line standard of care for HR + /HER2 − advanced breast cancer (ABC), yet no head-to-head trials comparing different CDK4/6 inhibitors have been conducted, and real-world comparative data in Chinese patients is currently unavailable. Methods We conducted a multicenter retrospective study of 341 Chinese patients with HR + /HER2 − ABC who received first-line palbociclib ( n = 177), abemaciclib ( n = 11